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Bevacizumab: the phoenix of breast oncology?
Bevacizumab is a monoclonal antibody that inhibits 
tumour neoangiogenesis mediated by VEGF. In a 
meta-analysis that included 2447 patients with breast 
cancer treated in a ﬁ rst-line setting, bevacizumab 
slightly improved progression-free survival (HR 0·64, 
95% CI 0·57–0·71; median 9·2 months vs 6·7 months) 
and did not improve overall survival (HR 0·97, 
95% CI 0·86–1·08; 26·7 months vs 26·4 months).1 
Guidelines recommend this drug as an option only 
in selected cases because of the slight improvement 
in progression-free survival, lack of beneﬁ t in overall 
survival, high cost, lack of predictive biomarkers, 
and associated toxicities.2 More recently, a phase 3 
randomised trial reported that bevacizumab did not 
improve outcome as adjuvant treatment in patients 
with triple-negative breast cancer.3 It is important 
to emphasise that this trial was done in patients 
with intermediate risk of relapse, and the eﬀ ect of 
bevacizumab in high-risk patients is still unknown. 
Overall, although the drug is still widely used in 
several countries, the enthusiasm associated with 
bevacizumab has dramatically decreased, and some 
countries have either restricted or stopped its use. 
In The Lancet Oncology, Helena Earl and colleagues4 
report pathological complete response results of a phase 
3 randomised trial assessing the eﬃ  cacy of bevacizumab 
in the neoadjuvant setting. A signiﬁ cantly greater 
proportion of patients treated with bevacizumab 
and chemotherapy achieved a pathological complete 
response (22% [95% CI 18–27]) compared with those 
treated with chemotherapy alone (17% [13–21]). The 
magnitude of improvement was numerically more 
pronounced in patients with oestrogen receptor (ER) 
negative (45% [95% CI 36–55] vs 31% [23–40]) or ER 
poor (51% [34–68] vs 30% [16–47]) breast cancer, as 
opposed to those with ER strongly positive breast cancer 
(6% [3–10] vs 7% [4–11]). 
The GeparQuinto, NSABP B-40, and CALGB 40603 
randomised trials have also assessed the eﬃ  cacy 
of bevacizumab in the neoadjuvant setting.5–7 All 
three trials5–7 reported that adding bevacizumab to 
chemotherapy could improve pathological complete 
response. Nevertheless, they did not report consistent 
data about which molecular subclass could derive 
greater beneﬁ t. GeparQuinto and CALGB 40603 
reported high beneﬁ t in triple-negative breast cancer, 
whereas NSABP B-40 reported higher beneﬁ t in 
ER-positive disease. Trials in the metastatic setting failed 
to show that patients with triple-negative breast cancer 
derived more beneﬁ t from bevacizumab than those 
with other subtypes. Overall, although they diverge on 
subgroup analyses, the four trials report consistent data 
that bevacizumab could increase pathological complete 
response in patients with early breast cancer. 
Although consistent, these data should not lead 
to the use of bevacizumab in early breast cancer for 
several reasons. First, a randomised trial3 in the adjuvant 
setting, although done in the earlier stages of breast 
cancer, was reported to be negative. Second, the 
improvement in pathological complete response was 
not dramatic in populations in which such response 
was assessed as a primary outcome. Nevertheless, this 
wave of randomised trials in the neoadjuvant setting, 
pending cooperation between the groups and support 
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from funding agencies, will certainly open a new era for 
the development of bevacizumab in breast cancer. 
First, these randomised trials will enable a meta-
analysis to be done. A meta-analysis will allow better 
understanding about which population derives more 
beneﬁ t, which chemotherapy backbone is the most 
appropriate, and will assess the eﬀ ect of bevacizumab 
on outcome (disease-free survival and overall survival) 
in a large population of patients presenting with high-
risk breast cancers. To what extent an improvement 
in pathological complete response translates into 
disease-free survival and overall survival beneﬁ t is still 
controversial in breast cancer, and this meta-analysis, 
based on a large number of patients, will certainly 
help. Second, neoadjuvant studies could allow the 
development of a molecular predictor for the eﬃ  cacy of 
bevacizumab. The predictor could be cross-validated in 
diﬀ erent trials because four studies are now available. 
Several molecular predictors have already been proposed, 
including vascular cell adhesion molecule 1, intercellular 
adhesion molecule 1, E-selectin, and circulating VEGFR-2.8 
Because most trials were done in a metastatic setting, 
no opportunity existed until now to test tissue-based 
biomarkers in samples obtained at baseline before 
therapy. Finally, neoadjuvant studies, where pre-
treatment and post-treatment samples are available, 
could allow the discovery of new mechanisms of action 
for bevacizumab. For example, bevacizumab has been 
reported to modulate the immune system through 
dendritic cells and regulatory T-cell functions, and could 
facilitate T-cell homing.9 If molecular analyses from 
neoadjuvant studies conﬁ rm an eﬀ ect of bevacizumab 
on the immune system, they could generate a rationale 
for triple combination therapy of immunogenic 
chemotherapy, anti-PD1 agents, and bevacizumab. 
Overall, the study by Earl and colleagues,4 consistent 
with previous trials, suggests that bevacizumab could 
improve pathological complete response in patients 
with breast cancer. These four trials could constitute the 
starting point of a new era for bevacizumab in breast 
oncology and could help to deﬁ ne which patients are 
more likely to beneﬁ t from bevacizumab, and which 
drug should optimally be combined with it.
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Parenthood in female survivors of Hodgkin’s lymphoma
In The Lancet Oncology, Jurgen Brämswig and colleagues1 
report pregnancy outcomes in 467 female long-term 
survivors of Hodgkin’s lymphoma who were younger 
than 18 years at diagnosis and treated in one of ﬁ ve 
concurrent clinical trials in Germany and Austria between 
1978 and 1995. The investigators are to be congratulated 
for this important contribution to the understanding of 
long-term pregnancy outcomes in female survivors of 
Hodgkin’s lymphoma. They have shown that the chance 
of these patients becoming a parent is similar to that in 
the female German population aged 16–39 years, and 
not signiﬁ cantly aﬀ ected by potentially gonadotoxic 
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